On the public citation graph

Dulaglutide

https://doi.org/10.1177/1060028014564180
0 signed · 73 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/s0140-6736(09)60659-0openalex-snapshot
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
inferredcites →https://doi.org/10.1016/s0140-6736(12)61267-7openalex-snapshot
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
inferredcites →https://doi.org/10.1016/s0140-6736(14)60976-4openalex-snapshot
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
inferredcites →https://doi.org/10.1016/s2213-8587(13)70214-6openalex-snapshot
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
inferredcites →https://doi.org/10.1111/1753-0407.12644openalex-snapshot
International Diabetes Federation 2017
inferredcites →https://doi.org/10.1111/j.1463-1326.2011.01364.xopenalex-snapshot
A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes
inferredcites →https://doi.org/10.1111/j.1463-1326.2011.01365.xopenalex-snapshot
LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects
inferredcites →https://doi.org/10.1111/j.1463-1326.2011.01366.xopenalex-snapshot
The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study
inferredcites →https://doi.org/10.1111/j.1464-5491.2012.03745.xopenalex-snapshot
Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study
inferredcites →https://doi.org/10.1136/bmjopen-2012-001986openalex-snapshot
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
inferredcites →https://doi.org/10.1161/hypertensionaha.114.03062openalex-snapshot
Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1210/jc.2010-2081openalex-snapshot
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
inferredcites →https://doi.org/10.1507/endocrj.ej14-0147openalex-snapshot
Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
inferredcites →https://doi.org/10.2337/dc09-1914openalex-snapshot
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
inferredcites →https://doi.org/10.2337/dc12-0413openalex-snapshot
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
inferredcites →https://doi.org/10.2337/dc13-2527openalex-snapshot
Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review
inferredcites →https://doi.org/10.2337/dc13-2759openalex-snapshot
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
inferredcites →https://doi.org/10.2337/dc13-2760openalex-snapshot
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
inferredcites →https://doi.org/10.2337/dc13-2761openalex-snapshot
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
inferredcites →https://doi.org/10.2337/dc14-s014openalex-snapshot
Standards of Medical Care in Diabetes—2014
inferredcites →https://doi.org/10.2337/diacare.29.02.06.dc05-1593openalex-snapshot
Standards of Medical Care in Diabetes
inferredcites →https://doi.org/10.4158/ep13176.csopenalex-snapshot
American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4161722openalex-extracted
Glucagon Like Peptide-1: More than Glucose Control and Weight Reduction
inferred← citeshttps://doi.org/10.1002/art.42540openalex-snapshot
Lysosome‐Associated Membrane Protein 3 Induces Lysosome‐Dependent Cell Death by Impairing Autophagic Caspase 8 Degradation in the Salivary Glands of Individuals With Sjögren's Disease
inferred← citeshttps://doi.org/10.1002/bip.23095openalex-snapshot
Peptibodies: An elegant solution for a long‐standing problem
inferred← citeshttps://doi.org/10.1002/psc.70039openalex-snapshot
Influence of Buffering Capacity, pH, and Temperature on the Stability of Semaglutide: A Preformulation Study
inferred← citeshttps://doi.org/10.1007/978-3-319-08982-9_2openalex-snapshot
Incretin hormones as a target for therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-08982-9_3openalex-snapshot
Glucagon-like peptide-1 receptor agonists
inferred← citeshttps://doi.org/10.1007/978-3-662-50351-5_3openalex-snapshot
Neue Arzneimittel 2015
inferred← citeshttps://doi.org/10.1007/s00125-017-4354-8openalex-snapshot
GLP-1/glucagon receptor co-agonism for treatment of obesity
inferred← citeshttps://doi.org/10.1007/s00253-015-7251-4openalex-snapshot
TAT-HSA-α-MSH fusion protein with extended half-life inhibits tumor necrosis factor-α in brain inflammation of mice
inferred← citeshttps://doi.org/10.1007/s10529-016-2049-8openalex-snapshot
Functional expression of human serum albumin-tandem thrombopoietin mimetic peptide fusion protein as a novel thrombopoietin analog in Pichia pastoris
inferred← citeshttps://doi.org/10.1007/s11883-016-0558-5openalex-snapshot
Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
inferred← citeshttps://doi.org/10.1007/s40262-015-0338-3openalex-snapshot
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
inferred← citeshttps://doi.org/10.1007/s42000-025-00649-zopenalex-snapshot
Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM
inferred← citeshttps://doi.org/10.1016/b978-0-443-44037-3.00655-2openalex-snapshot
Dulaglutide
inferred← citeshttps://doi.org/10.1016/j.biopha.2018.08.088openalex-snapshot
Recent updates on GLP-1 agonists: Current advancements & challenges
inferred← citeshttps://doi.org/10.1016/j.biopsych.2026.04.010openalex-snapshot
From the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
inferred← citeshttps://doi.org/10.1016/j.bmc.2016.01.036openalex-snapshot
A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus
inferred← citeshttps://doi.org/10.1016/j.coph.2021.09.001openalex-snapshot
Next-gen therapeutics to spare and expand beta-cell mass
inferred← citeshttps://doi.org/10.1016/j.japh.2021.06.015openalex-snapshot
Weight loss differences seen between glucagon-like peptide–1 receptor agonists and sodium–glucose cotransporter–2 inhibitors for treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2022.108270openalex-snapshot
Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities
inferred← citeshttps://doi.org/10.1016/j.psycr.2024.100231openalex-snapshot
Effect of GLP-1 receptor agonists on obesity in patients with severe mental illness: A state hospital case series of clozapine-treated patients
inferred← citeshttps://doi.org/10.1016/j.rmclc.2016.04.013openalex-snapshot
NUEVOS FÁRMACOS EN DIABETES MELLITUS
inferred← citeshttps://doi.org/10.1016/j.tem.2016.03.004openalex-snapshot
Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets
inferred← citeshttps://doi.org/10.1016/s0140-6736(19)31350-9openalex-snapshot
Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.9b00308openalex-snapshot
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
inferred← citeshttps://doi.org/10.1021/acsabm.3c00193openalex-snapshot
Recent Advances in Formulations for Long-Acting Delivery of Therapeutic Peptides
inferred← citeshttps://doi.org/10.1021/acsbiomaterials.8b00992openalex-snapshot
Supercritical Fluid-Assisted Decoration of Nanoparticles on Porous Microcontainers for Codelivery of Therapeutics and Inhalation Therapy of Diabetes
inferred← citeshttps://doi.org/10.1055/a-0885-1429openalex-snapshot
Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs
inferred← citeshttps://doi.org/10.1055/a-2928-5204openalex-snapshot
Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes
inferred← citeshttps://doi.org/10.1080/14712598.2017.1296131openalex-snapshot
Dulaglutide for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1097/med.0000000000000516openalex-snapshot
Incretin therapy for diabetes mellitus type 2
inferred← citeshttps://doi.org/10.1111/nyas.14211openalex-snapshot
Incretins in obesity and diabetes
inferred← citeshttps://doi.org/10.1177/0145721715607981openalex-snapshot
GLP-1 Receptor Agonists
inferred← citeshttps://doi.org/10.12688/f1000research.186847.1openalex-snapshot
Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.14341/dm9623openalex-snapshot
Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1530/joe-18-0264openalex-snapshot
Are peptide conjugates the golden therapy against obesity?
inferred← citeshttps://doi.org/10.1586/17512433.2016.1121808openalex-snapshot
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
inferred← citeshttps://doi.org/10.1586/17512433.2016.1141046openalex-snapshot
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.17925/ee.2015.11.01.21openalex-snapshot
GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1698787/v1openalex-snapshot
Transient suppression of ovarian function Induced by Dulaglutide: a case report and review of the literature
inferred← citeshttps://doi.org/10.2174/0115748855276929231218053337openalex-snapshot
Clinical Analysis of Resemblance and Dissimilarities of Glucagon-like Peptide-1 Receptor Agonists: Therapeutic Approach Towards the Management of Diabetes Mellitus
inferred← citeshttps://doi.org/10.3389/fendo.2023.1130470openalex-snapshot
Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
inferred← citeshttps://doi.org/10.3389/fphar.2026.1736083openalex-snapshot
Case study on adverse reactions of dulaglutide: literature review
inferred← citeshttps://doi.org/10.3389/fphys.2017.00294openalex-snapshot
Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice
inferred← citeshttps://doi.org/10.3390/biomedicines13092174openalex-snapshot
Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs
inferred← citeshttps://doi.org/10.3390/cancers12102992openalex-snapshot
FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1
inferred← citeshttps://doi.org/10.3390/microorganisms13051132openalex-snapshot
Gut Microbiota and Lipid Metabolism in Bullfrog Tadpoles: A Comparative Study Across Nutritional Stages
inferred← citeshttps://doi.org/10.36502/2019/asjbccr.6137openalex-snapshot
Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA)
inferred← citeshttps://doi.org/10.3892/etm.2020.9154openalex-snapshot
Abnormal metabolic processes involved in the pathogenesis of non‑alcoholic fatty liver disease (Review)
inferred← citeshttps://doi.org/10.4158/accr-2018-0192openalex-snapshot
Addition of Dulaglutide for a High-Dose Insulin Requiring Patient with Type 2 Diabetes Mellitus: A Remarkable Response
inferred← citeshttps://doi.org/10.5604/16652681.1171746openalex-snapshot
The treatment of diabetes mellitus of patients with chronic liver disease
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.